Hepatology International, Journal Year: 2025, Volume and Issue: unknown
Published: April 7, 2025
Language: Английский
Cancers, Journal Year: 2022, Volume and Issue: 14(16), P. 3972 - 3972
Published: Aug. 17, 2022
Cancer immunotherapy has revolutionized the field of oncology in recent years. Harnessing immune system to treat cancer led a large growth number novel immunotherapeutic strategies, including checkpoint inhibition, chimeric antigen receptor T-cell therapy and vaccination. In this review, we will discuss current landscape immuno-oncology research, with focus on elements that influence outcomes. We also highlight advances basic aspects tumor immunology, particular, role immunosuppressive cells within microenvironment regulating antitumor immunity. Lastly, how understanding immunology can lead development new strategies.
Language: Английский
Citations
82
Molecular Cancer, Journal Year: 2024, Volume and Issue: 23(1)
Published: Jan. 9, 2024
Abstract The CRISPR system is a revolutionary genome editing tool that has the potential to revolutionize field of cancer research and therapy. ability precisely target edit specific genetic mutations drive growth spread tumors opened up new possibilities for development more effective personalized treatments. In this review, we will discuss different CRISPR-based strategies have been proposed therapy, including inactivating genes tumor growth, enhancing immune response cells, repairing cause cancer, delivering cancer-killing molecules directly cells. We also summarize current state preclinical studies clinical trials highlighting most promising results challenges still need be overcome. Safety delivery are important therapy become viable option. limitations overcome, such as off-target effects, safety, site. Finally, provide an overview opportunities in future directions development. change landscape research, review aims overcome realize potential.
Language: Английский
Citations
72
Cells, Journal Year: 2023, Volume and Issue: 12(12), P. 1606 - 1606
Published: June 11, 2023
Adoptive cell therapy using chimeric antigen receptor (CAR) technology is one of the most advanced engineering platforms for cancer immunotherapy. CAR-T cells have shown remarkable efficacy in treatment hematological malignancies. However, their limitations solid tumors include an immunosuppressive tumor microenvironment (TME), insufficient infiltration, toxicity, and absence tumor-specific antigens. Although recent advances design-such as incorporation co-stimulatory domains development armored cells-have promising results treating tumors, there are still challenges that need to be addressed. To overcome these limitations, other immune cells, such natural killer (NK) macrophages (M), been developed attractive options efficient immunotherapy tumors. CAR-NK exhibit substantial clinical improvements with "off-the-shelf" availability low toxicity. CAR-M therapeutic potential because can infiltrate TME Here, we review future perspectives associated engineered cell-based immunotherapies We also summarize ongoing trials investigating safety CAR-T, CAR-NK, CAR-M, targeting
Language: Английский
Citations
44
Discover Oncology, Journal Year: 2024, Volume and Issue: 15(1)
Published: Aug. 11, 2024
Novel therapeutic agents in clinical trials offer a paradigm shift the approach to battling this prevalent and destructive disease, area of cancer therapy is on precipice trans formative revolution. Despite importance tried-and-true treatments like surgery, radiation, chemotherapy, disease continues evolve adapt, making new, more potent methods necessary. The field currently witnessing emergence wide range innovative approaches. Immunotherapy, including checkpoint inhibitors, CAR-T cell treatment, vaccines, utilizes host's immune system selectively target eradicate malignant cells while minimizing harm normal tissue. development targeted medicines kinase inhibitors monoclonal antibodies has allowed for less harmful approaches treating cancer. With help genomics molecular profiling, "precision medicine" customizes therapies each patient's unique genetic makeup maximize efficacy unwanted side effects. Epigenetic therapies, metabolic interventions, radio-pharmaceuticals, an increasing emphasis combination with synergistic effects further broaden landscape. Multiple-stage are essential determining safety these novel drugs, allowing patients gain access also furthering scientific understanding. future rife promise, as integration artificial intelligence big data potential revolutionize early detection prevention. Collaboration among researchers, healthcare providers, active involvement remain bedrock ongoing battle against In conclusion, dynamic evolving landscape provides hope improved treatment outcomes, emphasizing patient-centered, data-driven, ethically grounded we collectively strive towards cancer-free world.
Language: Английский
Citations
26
Molecular Cancer, Journal Year: 2024, Volume and Issue: 23(1)
Published: June 1, 2024
Abstract Significant advancements have been made in the application of chimeric antigen receptor (CAR)-T treatment for blood cancers during previous ten years. However, its effectiveness treating solid tumors is still lacking, necessitating exploration alternative immunotherapies that can overcome significant challenges faced by current CAR-T cells. CAR-based immunotherapy against shows promise with emergence macrophages, which possess robust phagocytic abilities, antigen-presenting functions, and ability to modify tumor microenvironment stimulate adaptive responses. This paper presents a thorough examination latest progress CAR-M therapy, covering both basic scientific studies clinical trials. study examines primary obstacles hindering realization complete potential as well strategies be employed these hurdles. With revolutionary technologies like situ genetic modification, synthetic biology techniques, biomaterial-supported gene transfer, provide wider array resources manipulating tumor-associated we suggest combining advanced methods will result creation new era therapy demonstrates improved efficacy, safety, availability. Graphical
Language: Английский
Citations
20
Journal of Translational Medicine, Journal Year: 2023, Volume and Issue: 21(1)
Published: March 28, 2023
Abstract Background Chimeric antigen receptor macrophage (CAR-M) therapy is a novel cancer immunotherapy approach that integrates CAR structure and functions. CAR-M has shown unique impressive antitumor effects in for solid tumors. However, the polarization state of macrophages can affect effect CAR-M. We hypothesized activity CAR-Ms may be further improved after inducing M1-type polarization. Methods In this report, we constructed HER2-targeting CAR-M, which was composed humanized anti-HER2 scFv, CD28 hinge region FcγRI transmembrane domain intracellular domain. Phagocytosis, tumor-killing capacities, cytokine release were detected with or without M1-polarization pretreatment. Several syngeneic tumor models used to monitor vivo M1-polarized CAR-Ms. Results After LPS combined interferon-γ vitro, found phagocytic capacities against target cells significantly enhanced. The expression costimulatory molecules proinflammatory cytokines also increased By establishing several vivo, demonstrated infusing polarized could effectively suppress progression prolong survival tumor-bearing mice enhanced cytotoxicity. Conclusions our eliminate HER2-positive both vitro M1 ability resulting stronger therapeutic immunotherapy.
Language: Английский
Citations
39
Drug Delivery and Translational Research, Journal Year: 2023, Volume and Issue: 13(7), P. 2041 - 2056
Published: Feb. 25, 2023
Language: Английский
Citations
37
Molecular Cancer, Journal Year: 2023, Volume and Issue: 22(1)
Published: March 31, 2023
Mantle cell lymphoma (MCL) is a subtype of Non-Hodgkin (NHL) mature B-cells characterized by translocation, which typically due to excess expression Cyclin D1. Although with the progress in our knowledge causes for MCL and available treatments MCL, this cancer still incurable. Age, male gender, rapid advancement, significant nodal involvement, elevated serum lactate dehydrogenase level, prognostic indications including increased Ki-67 presence TP53 mutation, are symbols poor outcome. Advanced immunotherapy using chimeric antigen receptor (CAR)-T cells advantageous patients suffering from B-cell malignancies MCL. Targeting antigens on surface feasible approach re-occurring (R/R) because responses obtained other cancers. USFDA has approved brexucabtagene autoleucel (Tecartus, KTE-X19), novel CAR T-cell therapy be used who have not responded previous or relapsed. The FDA new treatment depending outcomes ZUMA-2 clinical trial. Serious adverse reactions, moderate anti-tumor activity, allergen withdrawal, escape, limited tumor infiltration, trafficking major barriers successful therapy. This review brief synopsis development
Language: Английский
Citations
35
Journal of Translational Medicine, Journal Year: 2024, Volume and Issue: 22(1)
Published: May 1, 2024
Abstract Adoptive cell therapy has revolutionized cancer treatment, especially for hematologic malignancies. T cells are the most extensively utilized in adoptive therapy. Currently, tumor-infiltrating lymphocytes, receptor-transgenic and chimeric antigen receptor three main therapies. Tumor-infiltrating lymphocytes kill tumors by reinfusing enlarged that naturally target tumor-specific antigens into patient. have ability to specifically destroy tumor via precise recognition of exogenous receptors with major histocompatibility complex. Chimeric transfer genes specific structural domains activation signals cells, allowing attack without assistance Many barriers been demonstrated affect clinical efficacy therapy, such as heterogeneity loss, hard trafficking infiltration, immunosuppressive microenvironment exhaustion. Several strategies improve explored, including multispecific combination immune checkpoint blockade, targeting microenvironment, etc. In this review, we will summarize current status application, followed bottlenecks addition, discuss promising result even more incredible advancements solid if aforementioned problems can be handled. Graphical abstract
Language: Английский
Citations
12
Stem Cell Research & Therapy, Journal Year: 2024, Volume and Issue: 15(1)
Published: June 18, 2024
Abstract Chimeric antigen receptor (CAR)-T cell adoptive immunotherapy is a promising cancer treatment that uses genetically engineered T cells to attack tumors. However, this therapy can have some adverse effects. CAR-T cell-derived exosomes are potential alternative may overcome limitations. Exosomes small vesicles released by and carry variety of molecules, including proteins, RNA, DNA. They play an important role in intercellular communication be used deliver therapeutic agents cells. The application could make more clinically controllable effective. cell-free, which means they less likely cause reactions than combination effective way treat either alone. where cannot reach. appropriate both cellular exosomal platforms practicable for cancer. This offer safe cancers.
Language: Английский
Citations
8